Ezose, Hirosaki University Partner on Glycomics Research Targeting Prostate Cancer | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ezose Sciences and Hirosaki University in Japan today announced a glycomics research collaboration to identify new biomarkers for the prediction and monitoring of progress of prostate cancer and other urological cancers.

Under the terms of the deal, Hirosaki researchers will collect urine samples from well-characterized patients and control populations in Japan, and Ezose will analyze the samples using its GlycanMap platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.